Navigation Links
Analysis of Long-Term Vicriviroc Data Provides Evidence of Sustained Viral Suppression, Increased CD4 Cell Counts and Tolerability in Treatment-Experienced HIV-Infected Patients
Date:10/26/2008

ation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., USA, and its Web site is http://www.schering-plough.com.

SCHERING-PLOUGH DISCLOSURE NOTICE: The information in this press release includes certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the clinical development of and the potential market for vicriviroc. Forward-looking statements relate to expectations or forecasts of future events. Schering-Plough does not assume the obligation to update any forward-looking statement. Many factors could cause actual results to differ materially from Schering-Plough's forward-looking statements, including market forces, economic factors, product availability, patent and other intellectual property protection, current and future branded, generic or over-the-counter competition, the regulatory process, and any developments following regulatory approval, among other uncertainties. For further details of these and other risks and uncertainties that may impact forward-looking statements, see Schering-Plough's Securities and Exchange Commission filings, including Item 8.01 of the company's 8-K filed Oct. 21, 2008.

References

(1) Coakley E, et al. Second International Workshop Targeting HIV Entry. Oct. 20-21, 2006; Boston, MA, USA; No. 8.

(2) Dunkle LM, Greaves WL, et al. Long-Term Safety of Vicriviroc. 4
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
2. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
3. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
4. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
5. Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
6. New Analysis of Study Data Shows That Asacol(R) (Mesalamine) Delivers Rapid Symptom Relief for Ulcerative Colitis Patients
7. A Sociolinguistic Analysis of In-Office Dialogue Reveals Psychiatrists and Parents Have Significantly Different Perceptions on ADHD and Psychiatric Comorbidities
8. Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results
9. Results Of VYVANSE(TM) (lisdexamfetamine dimesylate) Effect Size Analysis Presented at Major Scientific Meeting
10. Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases
11. Retrospective Analysis Finds That Initiation of Insulin Glargine in Patients With Type 2 Diabetes was Associated With a Lower Incidence Rate of Myocardial Infarction as Compared With NPH Insulin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/4/2015)... Adding SIR-Spheres® Y-90 resin ... metastatic colorectal cancer in the liver (mCRC) further ... Patients with unresectable metastatic colorectal cancer (mCRC) that ... greatest improvement in Progression-Free Survival (PFS) in the ... microspheres to a current first-line chemotherapy regimen, according ...
(Date:7/3/2015)... , July 3, 2015 A ... of hypertension, diabetes and thyroid disorders in ... and a major conference dedicated to these diseases. ... Diabetes Online , Manage Hypertension Online and ... operated by EXCEMED - combine the world,s ...
(Date:7/2/2015)... 3 juillet 2015 BGI a annoncé aujourd,hui ... de l,ADN situé à Hong Kong ... College of Pathologists  (Collège des pathologistes américains, ou ... Hong Kong constituent le premier laboratoire ... la certification du CAP en Chine, car il ...
Breaking Medicine Technology:New SIRFLOX Study Data Presented at World Congress of Gastrointestinal Cancer 2New SIRFLOX Study Data Presented at World Congress of Gastrointestinal Cancer 3New SIRFLOX Study Data Presented at World Congress of Gastrointestinal Cancer 4Combating Three Major Chronic Diseases in Latin America With Medical Education 2BGI obtient la certification du Collège des pathologistes américains (CAP) 2
... 20, 2011 Reportlinker.com announces that a new ... Levosimendan - Comprehensive patent search ... Eliminate unnecessary risk with the industry benchmark ... is a regularly updated, professional patent search performed ...
... -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX ... outsourcing company with operations in China and the United ... for the first quarter of 2011 after the New ... (which will be Wednesday morning, May 11, 2011 Shanghai ...
Cached Medicine Technology:Reportlinker Adds Levosimendan - Comprehensive patent search 2Reportlinker Adds Levosimendan - Comprehensive patent search 3Reportlinker Adds Levosimendan - Comprehensive patent search 4WuXi PharmaTech Schedules First-Quarter 2011 Earnings Release 2
(Date:7/3/2015)... ... July 03, 2015 , ... Talcum powder attorneys representing clients ... existing Talcum Powder Cancer Lawsuit Center website. Just as the previous version did, the ... , offering timely lawsuit updates and ovarian cancer warning information. The site is routinely ...
(Date:7/3/2015)... , ... July 03, 2015 , ... Every year, One-to-1 ... Train-a-Thon where they provide members of the Red Deer community with free fitness training ... of fitness training, games, food, events and entertainment raised thousands of charity dollars and ...
(Date:7/2/2015)... ... , ... Following the recent report by JAMA Internal Medicine published ... Americans, Samir Becic emphatically declared a war on obesity in the United States. , ... "We must understand the magnitude of this discovery. For that reason, I am declaring, ...
(Date:7/2/2015)... ... ... In 2012, Patrick Achebe realized that the gift of poetry was fully in him, as ... first poem, and three years later he was publishing an entire book of poetry. He ... world. "I have always believed that the best way to lift yourself up, is in ...
(Date:7/2/2015)... ... 2015 , ... Six months ahead of his 80th birthday, Don Stevenson has ... money for the Pulmonary Hypertension Association (PHA). Stevenson began the walk in Washington ... by mid-September. He left Glasgow, Mont. yesterday morning and is making his way to ...
Breaking Medicine News(10 mins):Health News:Talcum Powder Lawsuit News: Cancer Attorneys Launch Updated Mobile Site 2Health News:Talcum Powder Lawsuit News: Cancer Attorneys Launch Updated Mobile Site 3Health News:Red Deer Fitness Studio Raises $10,000 for Charity Organization with 24-Hour Train-a-Thon 2Health News:Red Deer Fitness Studio Raises $10,000 for Charity Organization with 24-Hour Train-a-Thon 3Health News:Samir Becic's Health Fitness Revolution Declares War Against Obesity in America 2Health News:Samir Becic's Health Fitness Revolution Declares War Against Obesity in America 3Health News:Samir Becic's Health Fitness Revolution Declares War Against Obesity in America 4Health News:Patrick Achebe Releases Debut Book, Whispering Waves: Poems for Everyday Grace 2Health News:79-Year-old ‘Pacing Parson’ Passes 1,000-Mile Mark in Cross-Country Walk for Pulmonary Hypertension Association 2Health News:79-Year-old ‘Pacing Parson’ Passes 1,000-Mile Mark in Cross-Country Walk for Pulmonary Hypertension Association 3
... (BRONX, NY) The National Institute of Diabetes and ... of Health (NIH) has awarded Albert Einstein College of ... for the continuation of its Diabetes Research and Training ... supplemental grant for equipment and additional pilot and feasibility ...
... and a friend dares you to eat a raw crayfish ... a severe parasitic infection. Physicians at Washington University School of ... six people who had consumed raw crayfish from streams and rivers ... three have been diagnosed since last September; the latest in April. ...
... high-risk women opt for lumpectomy , TUESDAY, May 25 ... before surgery enhances their chances of being able to ... new research suggests. , The observation was based on ... United States. It focused on postmenopausal women who had ...
... suggest that bacteria residing in the the human intestinal ... developing colon cancer. Scientists from the University of Florida ... of the American Society for Microbiology in San Diego, ... are more frequently detected in subjects with polyps, early ...
... indicated higher, lower risk of disease, study finds , ... germs living in your gut could affect your risk ... signs of the existence of some germs "are more ... can develop into cancer, while other bacterial signatures are ...
... in French . Montreal, May 25, 2010 ... French and English, at local bookstores and pharmacies. Dr. Jean-Daniel ... Department of Ophthalmology, along with two colleagues from France, have ... Macular Degeneration (Annika Parance Publisher; 121 pages). Written to educate ...
Cached Medicine News:Health News:NIH awards $10M to Einstein for diabetes research 2Health News:NIH awards $10M to Einstein for diabetes research 3Health News:Dangerous lung worms found in people who eat raw crayfish 2Health News:Dangerous lung worms found in people who eat raw crayfish 3Health News:Dangerous lung worms found in people who eat raw crayfish 4Health News:Breast Cancer Study Offers New Hope 2Health News:Book on vision loss: AMD affects 1 million Canadians 2
Architect ci8200 is a flexible solution for your evolving laboratory offering high productivity, one report and one operator interface for both chemistry and immunoassay testing....
... The Bayer Immuno 1 ... access immunoassay instrument with over ... reproductive endocrinology, tumor marker, therapeutic ... testing can be performed on ...
The UniCel DxI 800 with its exceptional throughput, proven chemiluminescent technology, assay protocols like Access, Access 2, Synchron LXi 725 and load "on-the-fly" capability simplifies and automat...
... The Access immunoassay ... random access benchtop analyzer ... of assays, with panels ... reproductive, thyroid, infectious disease, ...
Medicine Products: